Revance Announces Closing of Public Offering of Common Stock

December 11, 2017

Gross Proceeds of Offering Total $167.1 Million

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the closing of an underwritten public offering of 6,139,515 shares of its common stock at a price to the public of $31.00 per share. In the offering, the Company issued and sold 5,389,515 shares, including the exercise in full by the underwriters of their option to purchase 550,806 additional shares of common stock from the Company, and certain stockholders of the Company (the "Selling Stockholders") sold 750,000 shares, including the exercise in full by the underwriters of their option to purchase 250,000 additional shares of common stock from the Selling Stockholders. The gross proceeds to the Company from the offering, before deducting the underwriters' discounts and other estimated offering expense payable by the Company, were approximately $167.1 million. The Company did not receive any proceeds from the sale of the shares by the Selling Stockholders.

Goldman Sachs & Co. LLC and Cowen acted as book-running managers, Barclays acted as joint lead manager, and Cantor Fitzgerald & Co., William Blair & Company, L.L.C. and SunTrust Robinson Humphrey acted as co-managers for the offering.

A shelf registration statement relating to the securities described above was filed with the Securities and Exchange Commission on December 5, 2017 and automatically became effective the same day. The offering was made only by means of a prospectus supplement. Copies of the final prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Revance Therapeutics, Inc.

Revance is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. Revance is leveraging its proprietary portfolio of botulinum toxin type A compounds, formulated with its patented and proprietary peptide technology, to address unmet needs in large and growing neurotoxin markets.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
General Media:
Mariann Caprino, 917-242-1087
Trade Media:
Nadine Tosk, 504-453-8344

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media